Abionyx Pharma SA (ABNX) - Net Assets
Based on the latest financial reports, Abionyx Pharma SA (ABNX) has net assets worth €5.41 Million EUR (≈ $6.33 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€12.98 Million ≈ $15.17 Million USD) and total liabilities (€7.56 Million ≈ $8.84 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore ABNX asset base for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €5.41 Million |
| % of Total Assets | 41.72% |
| Annual Growth Rate | 1.71% |
| 5-Year Change | 11.99% |
| 10-Year Change | -77.64% |
| Growth Volatility | 79509.15 |
Abionyx Pharma SA - Net Assets Trend (2013–2024)
This chart illustrates how Abionyx Pharma SA's net assets have evolved over time, based on quarterly financial data. Check tangible equity quality of Abionyx Pharma SA to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Abionyx Pharma SA (2013–2024)
The table below shows the annual net assets of Abionyx Pharma SA from 2013 to 2024. For live valuation and market cap data, see ABNX market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €7.42 Million ≈ $8.68 Million |
-6.29% |
| 2023-12-31 | €7.92 Million ≈ $9.26 Million |
+10.50% |
| 2022-12-31 | €7.17 Million ≈ $8.38 Million |
-32.86% |
| 2021-12-31 | €10.68 Million ≈ $12.48 Million |
+61.07% |
| 2020-12-31 | €6.63 Million ≈ $7.75 Million |
-0.56% |
| 2019-12-31 | €6.67 Million ≈ $7.79 Million |
+73.73% |
| 2018-12-31 | €3.84 Million ≈ $4.49 Million |
-56.83% |
| 2017-12-31 | €8.89 Million ≈ $10.39 Million |
-39.16% |
| 2016-12-31 | €14.61 Million ≈ $17.08 Million |
-55.99% |
| 2015-12-31 | €33.20 Million ≈ $38.81 Million |
+276558.33% |
| 2014-12-31 | €12.00K ≈ $14.03K |
-99.81% |
| 2013-12-31 | €6.16 Million ≈ $7.20 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Abionyx Pharma SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 11126800000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €1.00K | 0.01% |
| Common Stock | €1.75 Million | 23.53% |
| Other Comprehensive Income | €-2.59 Million | -34.85% |
| Other Components | €8.26 Million | 111.30% |
| Total Equity | €7.42 Million | 100.00% |
Abionyx Pharma SA Competitors by Market Cap
The table below lists competitors of Abionyx Pharma SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Games Workshop Group PLC
LSE:GAW
|
$77.15 Million |
|
Mordechai Aviv Taasiot Beniyah 1973 Ltd
TA:AVIV
|
$77.18 Million |
|
Atlas Lithium Corporation Common Stock
NASDAQ:ATLX
|
$77.19 Million |
|
Starry Sea Acquisition Corp Ordinary Shares
NASDAQ:SSEA
|
$77.20 Million |
|
Subex Limited
NSE:SUBEXLTD
|
$77.11 Million |
|
Country View Bhd
KLSE:5049
|
$77.08 Million |
|
Grimoldi SA
BA:GRIM
|
$77.07 Million |
|
Symphony Communication Public Company Limited
BK:SYMC
|
$77.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Abionyx Pharma SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,922,000 to 7,424,000, a change of -498,000 (-6.3%).
- Net loss of 4,400,000 reduced equity.
- Share repurchases of 24,000 reduced equity.
- New share issuances of 3,358,000 increased equity.
- Other comprehensive income decreased equity by 25,000.
- Other factors increased equity by 593,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-4.40 Million | -59.27% |
| Share Repurchases | €24.00K | -0.32% |
| Share Issuances | €3.36 Million | +45.23% |
| Other Comprehensive Income | €-25.00K | -0.34% |
| Other Changes | €593.00K | +7.99% |
| Total Change | €- | -6.29% |
Book Value vs Market Value Analysis
This analysis compares Abionyx Pharma SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.49x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 5.40x to 8.49x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | €0.35 | €1.87 | x |
| 2014-12-31 | €0.00 | €1.87 | x |
| 2015-12-31 | €2.00 | €1.87 | x |
| 2016-12-31 | €0.75 | €1.87 | x |
| 2017-12-31 | €0.49 | €1.87 | x |
| 2018-12-31 | €0.21 | €1.87 | x |
| 2019-12-31 | €0.32 | €1.87 | x |
| 2020-12-31 | €0.29 | €1.87 | x |
| 2021-12-31 | €0.43 | €1.87 | x |
| 2022-12-31 | €0.26 | €1.87 | x |
| 2023-12-31 | €0.27 | €1.87 | x |
| 2024-12-31 | €0.22 | €1.87 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Abionyx Pharma SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -59.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -95.65%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.81x
- Recent ROE (-59.27%) is above the historical average (-4622.96%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -125.64% | 0.00% | 0.00x | 2.26x | €-8.36 Million |
| 2014 | -54691.67% | 0.00% | 0.00x | 903.08x | €-6.56 Million |
| 2015 | -50.12% | 0.00% | 0.00x | 1.39x | €-19.96 Million |
| 2016 | -170.23% | 0.00% | 0.00x | 1.99x | €-26.33 Million |
| 2017 | -56.01% | 0.00% | 0.00x | 2.06x | €-5.87 Million |
| 2018 | -164.32% | -3623.56% | 0.01x | 3.42x | €-6.69 Million |
| 2019 | 27.74% | 0.00% | 0.00x | 1.54x | €1.18 Million |
| 2020 | -28.45% | 0.00% | 0.00x | 1.55x | €-2.55 Million |
| 2021 | -54.53% | -862.52% | 0.03x | 2.04x | €-6.89 Million |
| 2022 | -58.67% | -80.08% | 0.33x | 2.21x | €-4.92 Million |
| 2023 | -44.41% | -75.82% | 0.31x | 1.87x | €-4.31 Million |
| 2024 | -59.27% | -95.65% | 0.34x | 1.81x | €-5.14 Million |
Industry Comparison
This section compares Abionyx Pharma SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $23,271,478
- Average return on equity (ROE) among peers: -66.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Abionyx Pharma SA (ABNX) | €5.41 Million | -125.64% | 1.40x | $77.13 Million |
| Abivax SA (ABVX) | $56.72 Million | -25.23% | 0.07x | $8.28 Billion |
| Adocia (ADOC) | $42.76 Million | -18.46% | 0.84x | $90.13 Million |
| Aelis Farma SA (AELIS) | $13.20 Million | -38.47% | 0.99x | $16.16 Million |
| Biophytis S.A. (ALBPS) | $4.52 Million | -176.01% | 0.86x | $1.97 Million |
| Cellectis (ALCLS) | $84.69 Million | -119.32% | 2.95x | $205.89 Million |
| Advicenne (ALDVI) | $-1.67 Million | 0.00% | 0.00x | $27.80 Million |
| Genoway (ALGEN) | $9.00 Million | -7.64% | 2.06x | $31.09 Million |
| Integragen (ALINT) | $1.28 Million | -213.59% | 2.27x | $1.00 Million |
| Medesis Pharma SA (ALMDP) | $-1.06 Million | 0.00% | 0.00x | $1.80 Million |
About Abionyx Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle that contains human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimic the structural and fu… Read more